Moderna Merck vaccinations trial lifts stocks after data
An experimental personalized cancer vaccine from Moderna and Merck showed positive initial Phase 3 results in melanoma patients after surgery, extending recurrence-free time versus Keytruda alone. The vaccinations approach also cut distant spread risk, sending Moderna shares up about 177% and Merck more than 12%.
Key Takeaways
- Moderna and Merck’s personalized mRNA cancer vaccine plus Keytruda met key Phase 3 goals in resected higher-risk melanoma.
- The combination extended time without recurrence and reduced risk of distant spread versus Keytruda alone.
- Moderna stock soared about 177% and Merck climbed more than 12% on the news.
- Regulator talks may begin in coming months; overall survival data are still being collected.
- The same vaccinations platform is also being studied in other tumor types.
What did the late-stage cancer vaccinations trial find?
Merck and Moderna said their experimental personalized cancer vaccine, used with Merck’s immunotherapy Keytruda, delivered positive initial results in its first late-stage trial. The Phase 3 study enrolled more than 1,100 patients with higher-risk or advanced melanoma whose detectable cancer had been completely removed by surgery.
Compared with Keytruda alone, the combination significantly extended the time patients lived without melanoma returning. It also reduced the risk that cancer would spread to distant parts of the body. Those outcomes build on earlier positive Phase 2 data for the same regimen, according to CNBC.
Melanoma makes up only about 1% of skin cancers but causes most skin-cancer deaths. Most recurrences appear within the first two to three years after initial treatment and removal, raising the stakes for adjuvant care after surgery.
How do these personalized vaccinations work?
Every tumor carries a unique mutation profile, even among patients with the same cancer type. The Merck-Moderna shot is designed to target each patient’s tumor-specific markers rather than use a one-size-fits-all vaccine. The goal is to train the immune system to recognize and kill those markers, then pair that response with Keytruda so the body can attack cancer more effectively.
Dr. Jane Healy, Merck’s head of oncology early development, called the improvement over Keytruda “clinically meaningful” and said the therapy was well tolerated. Side effects were similar to other vaccines people typically receive, she told CNBC. Moderna CEO Stephane Bancel called it “a big moment for medicine, a big moment for patients.”
Why did Moderna and Merck stocks soar?
Investors treated the readout as a major validation. Moderna’s market value was near $25 billion entering the session, versus about $333 billion for Merck, helping explain why Moderna’s roughly 177% jump outpaced Merck’s more than 12% gain. Analysts had framed the Phase 3 melanoma result as a make-or-break event for Moderna’s stock, with valuation expectations already tied to the vaccine’s potential across multiple cancers.
The companies are also testing the approach in other cancers, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma. That pipeline potential amplified the market reaction to the melanoma data.
What happens next for approval and patients?
The Phase 3 study will continue to assess other outcomes, including overall survival. The drugmakers plan to present the data at an upcoming international medical meeting. Timing for U.S. approval filings remains unclear.
Dr. Dean Li, president of Merck Research Laboratories, said the companies will likely start talking with regulatory agencies about the treatment and its safety “in the next few months.” For readers following wider BlasterPost coverage, browse our True Crime & Unsolved Mysteries category hub.
If confirmed and cleared by regulators, the combination could become a new option after surgery for people facing the deadliest form of skin cancer—and a template for personalized vaccinations in other tumors.